Abstract
Since the beginning of the pandemic, molecular methods such as real-time RT-PCR have been used as references for severe acute respiratory syndrome (SARS-CoV-2) detection. With unprecedented demands for SARS-CoV-2 testing, and difficulties acquiring NAAT supplies, clinical laboratories are challenged with providing timely results. Rapid diagnostic tests (RDTs) are simple, rapid, and portable technologies that offer a potential solution to increase the diagnostic testing capacity. Recently, some RDTs have become licensed under emergency use authorization for SARS-CoV-2 detection in the laboratory or point-of-care settings (Food and Drug Administration (FDA), 2020), but despite their high specificity, the applicability of RDTs has been hampered by poor clinical sensitivity, which often falls below the ideal target product profiles recommended by the World Health Organization (Dinnes et al., 2020; World Health Organization (WHO), 2020a; World Health Organization (WHO), 2020b).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
